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Chronic exposure of humans to benzene (BZ) causes acute myeloid leukemia (AML). Both BZ and
therapy-related secondary AML are characterized by chromosomal translocations that may occur
by inappropriate recombinational events. DNA topoisomerase 11 (topo 11) is an essential sulfhydryl
(SH)-dependent endonuclease required for replication, recombination, chromosome segregation,
and chromosome structure. Topo II cleaves DNA at purine(R)/pyrimidine(Y) repeat sequences that
have been shown to be highly recombinogenic in vivo. Certain antineoplastic drugs stabilize topo
Il-DNA cleavage complexes at RY repeat sequences, which leads to translocations of the type
observed in leukemia. Hydroquinone (HQ) is metabolized to p-benzoquinone (BQ) in a peroxidase-
mediated reaction in myeloid progenitor cells. BQ interacts with SH groups of SH-dependent
enzymes. Consequently, the aims of this research were to determine whether HQ and BQ are
topo 11 inhibitors. The ability of the compounds to inhibit the activity of topo 11 was tested using an
assay system that depends on the conversion, by homogeneous human topo 11, of catenated
kinetoplast DNA into open and/or nicked open circular DNA that can be separated from the
catenated DNA by electrophoresis in a 1 % agarose-ethidium bromide gel. We provide
preliminary data that indicate that both HQ and BQ cause a time and concentration
(pMl-dependent inhibition of topo 11 activity. These compounds, which potentially can form
adducts with DNA, have no effect on the migration of the supercoiled and open circular forms in
the electrophoretic gradient, and BQ-adducted KDNA can be decatenated by topo 11. Using a
pRYG plasmid DNA with a single RY repeat as a cleavage site, it was determined that BQ does
not stimulate the production of linear DNA indicative of an inhibition of topo 11 religation of strand
breaks by stabilization of the covalent topo Il-DNA cleavage complex. Rather, BQ most probably
inhibits the SH-dependent topo 11 by binding to an essential SH group. The inhibition of topo 11 by BQ
has implications for the formation of deleterious translocations that may be involved in BZ-induced
initiation of leukemogenesis. - Environ Health Perspect 104(Suppl 6):1265-1269 (1996)
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Introduction
Benzene (BZ), a widely used industrial (HQ) are transported to the bone marrow
chemical and ubiquitous environmental (7,8) and further oxidized in a peroxidase-
pollutant, is a Class I carcinogen that mediated (9-11) reaction to biologically
causes secondary acute myelogenous leuke- reactive intermediates such as p-benzoqui-
mia (AML) in humans who are chronically none (BQ), which can interact with the
exposed (1-4). Benzene hematotoxicity genome and potentiallyaffect hematopoiesis.
occurs when its hepatic metabolites (5,6), Because of the association between BZ
such as phenol, catechol and hydroquinone exposure and an increased incidence of
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AML, it is important to determine whether
BZ can cause genotoxic effects of the
types observed in secondary AML (4).
Cytogenetic studies of the karyotypes of
workers occupationally exposed to BZ have
demonstrated the presence of nonrandom
chromosomal aberrations such as breaks,
gaps, and-infrequently-rearrangements
on chromosomes 2, 4, and 7 (12,13). In
another study (14), an individual whose
exposure to BZ was considered to be high,
showed a reciprocal familial chromosomal
translocation [t(3;16)(ql 1;ql 1)] and kary-
otype abnormalities in 100% of the mar-
row cells, which included t(9;10) and
t(4;15) translocations. A t(4;I1) (q21;q23)
has been reported in a furniture worker
who had a "benzene intoxication" for 3
months prior to the development of acute
lymphoblastic leukemia (ALL) (15). This
translocation has also been reported (16)
in an individual with therapy-related
myelodysplasia (preleukemia).
Topo II, a sulfhydryl (SH)-dependent
endonuclease essential for replication,
recombination, chromosome segregation,
and chromosome structure (17), catalyzes
the :elaxation of supercoiled DNA by the
transient cleavage and religation of both
strands of duplex DNA (17). It cleaves
DNA at purine(R)/pyrimidine(Y) repeat
sequences (18) that have been shown to be
highly recombinogenic in eukaryotes in
vivo (19,20). There appears to be sequence
homology between topo II cleavage sites
and the sequences at the t(4;11) and
t(9;I 1) translocation breakpoint junctions,
suggesting that topo II may function in
chromosomal translocations at chromoso-
mal band 11q23.The epipodophyllotoxin
class ofantineoplastic drugs enhances topo
II-mediated chromosomal breakage by sta-
bilizing the topo II-DNA cleavage com-
plex and thus decreasing the religation of
the nicked DNA strands (17) and resulting
in chromosomal changes at the cellular
level of the types observed in leukemia.
The nonrandom association of 1 lq23
chromosomal translocations with epipodo-
phylotoxin chemotherapy suggests that the
1lq23 translocation breakpoints within the
MLL gene may coincide with cleavage sites
for topo II. Epipodophyllotoxin-induced
in vitro topo II cleavage sites do, in fact,
correspond with chromosome 1 1q23
translocation breakpoints (C Felix and
M-A Bjornsti, personal communication).
BQ, in common with the antineoplastic
drugs, is an alkylating agent that has a high
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propensity to react with SH groups of
proteins and has been shown to inactivate
several SH-dependent proteins (21-24).
The fact that these quinones also induce
chromosomal aberrations suggests that
they might be affecting chromosomal
translocations by inhibition oftopo II.
We report preliminary results that
indicate that both HQ and BQ, at micro-
molar concentrations, cause the concentra-
tion-dependent inhibition of topo II
activity, probably by interaction with an
essential SH group of topo II rather than
by stabilization ofthe topo II-DNA cleav-
age-religation complex.
Materials and Methods
Materials
Ehtylenediaminetetraacetate (EDTA), chlo-
roform, isoamyl alcohol, HQ, and BQ,
were obtained from Fisher Scientific Co.
(Pittsburgh, PA). Electrophoresis grade aga-
rose was purchased from Bethesda Research
Laboratories (Bethesda, MD), and ethid-
ium bromide (EtBr), Sarkosyl, bromphenol
blue, and glycerol were obtained from the
Sigma Chemical Co. (St Louis, MO).
Boehringer Mannheim (Indianapolis, IN)
was the source of proteinase K. Homo-
geneous human placental topo II (170
kDa) was obtained from TopoGen, Inc.
(Columbus, OH). The enzyme was free of
topo I activity and nuclease contamina-
tion. A unit of topo II activtiy is that
amount ofenzyme that decatenates 0.2 pg
ofcatenated kinetoplast DNA (KDNA) in
15 min at 37°C. KDNA, catenated mito-
chondrial DNA of Crithidiafasciculata,
decatenated KDNA (dKDNA), linear
KDNA (IKDNA), supercoiled pRYG
DNA, linear pRYG DNA (lpRYG DNA),
lOx assay, cleavage and gel-loading buffers
and 5x stop buffer, and sodium dodecyl
sulfate (SDS) were also obtained from
TopoGen, Inc. All other reagents were of
the highest grade available.
Methods
Topo IIAssay. The activity oftopo II was
tested using an assay system that depends
on the conversion by topo II of highly
catenated KDNA into open and/or nicked
open circular DNAs. KDNA is an aggre-
gate ofinterlocked DNA minicircles of2.5
kb that form a large network of high
molecular weight DNA that does not pen-
etrate an agarose gel matrix. Incubation
of KDNA with topo IL results in decate-
nation of KDNA with the release of
minicircular decatenated KDNAs that
electrophoretically migrate rapidly into an
agarose gel.
The standard reaction contained 0.2 pg
KDNA and 2 u of topo II in 50 mM
Tris-HCl buffer, pH 8.0, containing 120
mM KCI, 10 mM MgCl2, 0.5 mM ATP,
0.5 mM DTT in a final volume of20 p1.
Incubation was carried out at 37°C for 15
min and terminated by the addition of4 p1
of stop/loading buffer consisting of 5%
Sarkosyl, 0.0025% bromphenol blue, 25%
glycerol. Marker DNAs were run to con-
firm the type ofdecatenated product pro-
duced in the reaction. Fifteen microliters of
mixture generally containing 0.15 pg DNA
was loaded into a well ofa 1% agarose gel
containing 0.16 pg/mi EtBr in 1x Tris-
acetate (TAE) buffer. Gels were run at
room temperature at a constant voltage of
50 mV for 4 hr. The 1% agarose gel has a
range of separation of linear DNA mole-
cules of 0.5 to 7 kb. The gels were dried
and the positions ofthe various species of
DNA in the gel were localized, in compari-
son with DNA markers, by exposure ofthe
EtBr-intercalated DNA to ultraviolet light.
Analysis ofthe ability of HQ and BQ
to inhibit topo II activity was carried out
using the same assay except that the com-
pounds were preincubated for 15 min with
topo II at concentrations listed in the leg-
end to Figure 1. The concentrations ofthe
metabolites stated were in excess of the
essential concentration of DTT in the
enzyme preparation.
Assay to Determine Whether
HQ and BQ Inhibit Topo 11 by
Stabilization ofthe
Topo Il-mediated DNA
Cleavage-Religation Complex
Eucaryotic topo II preferentially cleaves
alternating purine/pyrimidine repeat
sequences in DNA (18). A plasmid con-
struct (pRYG) consisting ofpUC19 plas-
mid containing a 245-bp fragment of the
human P-globin gene promoter with a
54-bp purine (R)/pyrimidine (Y) repeat
sequence that serves as a high-affinity
topo II recognition and cleavage site was
used as a substrate. In a cleavage assay,
pRYG allows the detection oftwo kinds of
topo II inhibitors: those that stimulate for-
mation of cleavable complexes such as the
antineoplastic drugs teneposide (VM-26)
and mAMSA, and agents that antagonize
topo II action on the DNA (i.e., may inter-
act with the active site ofthe enzyme). The
cleavage assay is based on the production
of a linear pRYG cleavage product in
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Figure 1. The decatenation of catenated kinetoplast
DNA as a function of topo 11 units. KDNA (0.2 pg) was
incubated for 30 min at 37°C with varying units of
human placental topo 11 in 50 mM Tris-HCI buffer, pH
8.0, containing 120 mM KCI, 10 mM MgCI2, 0.5 mM
ATP, 0.5 mM DTT in a final volume of 20 p1. The reac-
tion was terminated bythe addition of4 p1 of stop/load-
ing buffer consisting of 5% Sarkosyl, 0.0025%
bromphenol blue, and 25% glycerol. A 15-pl sample
(0.15 pg DNA) was loaded into each well of a 1%
agarose/2 pg/ml ethidium bromide gradient. The gel
was run at room temperature ata constantvoltage fora
length of time (generally 4 hr) sufficient to allow the
migration of the smallest DNAs to traverse 80% of the
length of the gel. Bands were visualized by exposure of
the gel to UV light and photographed. KDNA, catenated
kinetoplast DNA marker; dKDNA, decatenated KDNA
marker.
the presence of agents that stabilize the
covalent topo II-DNA cleavage complex
by inhibiting the topo I-mediated
religation reaction.
In the cleavage reaction, pRYG plasmid
(0.25 pg) was incubated with 3 to 6 units
oftopo II in 30 mM Tris-HCl buffer, pH
7.6, containing 3 mM ATP, 15 mM mer-
captoethanol, 8 mM MgCI2, 60 mM NaCl
in a final volume of 20 p1l. BQ was added
at a concentration of 20 to 200 pM over
the concentration of mercaptoethanol in
the reaction. Incubation was carried out at
37°C for 30 min. The reaction was termi-
nated by the addition of2 pl of 10% SDS.
The mixture was digested with proteinase
K (50 pg/mi) for 15 min and extracted
with an equal volume of chloroform:
isoamyl alcohol (24:1). The upper phase
(20 pil) was loaded into a well of a 1%
agarose gel containing 2 pg/ml EtBr.
Results
Decatenation ofKDNAbyTopo II
Incubation of topo II (2-12 units) with
KDNA resulted in a concentration-depen-
dent decatenation ofKDNA into open and
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Figure 2.The effect of HQ and BQ on the elec-
trophoretic mobility of the various species of KDNA
produced in the topo 11 decatenation assay. KDNA,
dKDNA, and IKDNA marker DNAs (0.2 pg) were
reacted with 6 pM HQ or BQ and subjected to gel elec-
trophoresis as described in the caption to Figure 1.
nicked open circular DNA (Figure 1). The
amount ofdecatenation that occurred was
a function of time and temperature (data
not presented). Thirty minutes at 37°C
were found to be optimal. This experiment
is representative of four experiments that
gave identical results.
Effect ofHydroquinone and
p-Benzoquinone ontheAbilityof
Topo II to Decatenate KDNA
It is well known that HQ and BQ form
covalent adducts with DNA (25). There-
fore, it was necessary to ascertain whether
the formation of adducts with KDNA
during the course of the reaction had any
effect on the migration in the electrophor-
etic gradient of any of the DNA species
produced. The gel profile presented in
Figure 2 shows that incubation ofthe vari-
ous marker DNAs with HQ or BQ at the
highest concentration (6 jiM) ofmetabolite
used in the assay for inhibition of topo II
decatenation of KDNA had no effect on
the electrophoretic migration of the DNA
marker species in the gel. To determine
whether BQ-adducted DNA interferred
with the ability of topo II to decatenate
KDNA, KDNA was reacted with 6 pM
BQ for 1 hr at 37°C (topo II assay condi-
tions) to allow KDNA to form any possible
adducts with BQ. The unreacted BQ was
removed and the BQ-adducted KDNA was
used, along with KDNA, as substrate in
the topo II decatenation assay. As can be
seen in Figure 3, the presence of BQ-
adducted KDNA did not interfere with the
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Figure 3.Decatenation of BQ-
adducted KDNA by topoisomerase
11. KDNA (75 pg) was incubated for
1 hr at 37°C with 6 pM BQ to form
KDNA adducts. The unreacted BO
was removed by treatment with
excess 2-mercaptoethanol and the
BQ-mercaptoethanol separated
from the BQ-adducted KDNA by gel
exclusion chromatography. Both
DNAs (0.2 pg/well) were added to
the wells of a 1% agarose/ethidium
bromide gel and electrophoresed as
described in the caption to Figure 1.
cleavage and religation reactions of topo II
on the basis that the same DNA species
were produced from both BQ-adducted
KDNA and KDNA. Topo II is very sensi-
tive to salt concentrations; consequently,
HQ and BQwere prepared and/or diluted
in deionized water to maintain the optimal
salt concentration in the reaction.
The ability of HQ and BQ to inhibit
the decatenation of KDNA by topo II was
tested. Preincubation of topo II with HQ
or BQ for 15 min over a concentration
range of 1 to 6 jiM prior to incubation with
KDNA caused a concentration-dependent
inhibition of topo II decatenation of
KDNA. BQinhibited at a concentration of
3 pM or higher, as indicated by the lack of
decatenated and/or open or nicked open
circular forms ofDNA (Figure 4). HQdid
not show inhibition oftopo II at 3 pM but
showed a complete inhibition at 6 pM.
The experiment presented is representative
ofthree similar experiments.
EffectofHydroquinone and
p-Benzoquinone onthe
Topo II-mediated DNA
Cleavag-Religation Reaction
Several potent and clinically relevant
antineoplastic agents known to cause sec-
ondary leukemia stabilize the topo II-DNA
cleavage complex by inhibiting the topo II-
mediated religation reaction (17,26). When
this stabilization occurs, the DNAfragments
resulting from the double-strand breaks
appear in the gel as a linear species. As can
be seen in Figure 5, when topo II was incu-
bated in the cleavage assay with pRYG plas-
mid, which contains a single RY topo II
cleavage site, in the presence of 200 pM
BQ, no linear pRYG DNA was produced.
BQ, at 60 times the concentration that
inhibits topo II activity in the decatenation
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Figure4. Inhibition oftopo 11 activity by HQand BQ. Topo
11 (2 U) was preincubated with the stated concentrations
of HQ or BO for 15 min at 37°C before the addition of
KDNA (0.2 pg), after which the reaction was allowed to
proceed for 30 min. The gel was loaded and the elec-
trophoresis of the products of the reaction was carried
out as described in the caption to Figure 1.
Abbreviations: KDNA catenated kinetoplast DNA,
dKDNA decatenated kDNA.
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Figure 5. The effect of BQ on the topo 11-mediated
cleavage-religation complex. pRYG plasmid (0.25 pg)
containing a high-affintiy topo 11 purine-pyrimidine
repeat sequence was incubated with 6 U of topo 11 in
cleavage buffer consisting of 30 mM Tris-HCI, pH 7.6,
3 mM ATP, 15 mM 2-mercaptoethanol, 8 mM MgC12,
and 60 mM NaCI. Because of the 15 mM 2-mercap-
toethanol in the reaction to protect the SH of topo 11, it
was necessary to add excess BO over the amount of
mercaptoethanol that will react with the BQ.
Consequently, BO was added at a concentration of
200 pM overthe concentration of2-mercaptoethanol in
the reaction. The reaction was carried out for 30 min at
37°C and was terminated by the addition of 2 pl of
10% SDS. The mixture was digested with proteinase K
and extracted with chloroform:isoamyl alcohol (24:1). A
sample of the upper phase was loaded onto a 1%
agarose/EtBr gel and electophoresed.
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assay, appears unable to stabilize the topo
II-mediated DNA cleavage-religation
complex. Similar results were obtained at
concentrations ofBQ between 20 and 200
pM. Although not shown in this gel, linear
DNA was produced from pRYG DNA by
topo II when the incubation was carried
out in the presence of200 pM mAMSA,
an agent that stabilizes the cleavage com-
plex. This experiment was carried out 4
times with identical results.
Discussion
Topo II is involved in many fundamental
processes occurring on the chromosome,
including recombination events (27).
Central to the physiological function of
topo II is its ability to introduce and reli-
gate site-specific double-stranded breaks in
the genome. Topo II serves as a therapeutic
target for various antibacterial, antiparasitic
antifungal, antiviral, and antineoplastic
drugs (26). These therapeutic drugs inter-
fere with the cleavage-religation reaction of
topo II by stabilizing the cleaved state as an
enzyme-DNA-drug ternary cleavable
complex. Topo II is a SH-dependent
endonuclease and as such is inhibited by
agents that form covalent adducts with SH
groups. Both BZ-induced and therapy-
related AML are characterized by chromo-
somal translocations or deletions that may
occur by inappropriate recombinational
events and may cause the conversion ofa
protooncogene to an oncogene or the loss
ofa suppressor gene resulting in the initia-
tion of leukemogenesis. These events may
occur by inhibition ofthe activity oftopo
II via an effect on an essential SH group or
by the stabilization of the topo II-DNA
cleavage complex.
HQ is converted in a peroxidase-medi-
ated reaction in the myeloblast to BQ that
covalently binds to SH-dependent proteins
and inhibits their activity. Consequently, it
was important to ascertain whether HQ or
BQ could affect the activity oftopo II and
thus play a possible role in the initiation
of BZ-induced AML. BQ was found to
inhibit, in a concentration-dependent man-
ner, the decatenation ofhighly catenated
kinetoplast DNA by human placental topo
II (Figure 4), whereas HQ only showed
inhibition at the highest level tested, 6 pM.
The ability of the compounds to form
adducts with the KDNA substrate had no
effect either on the migration ofthe decate-
nated supercoiled and open circular
products in the electrophoretic gradient
(Figure 2) or the ability oftopo II to use
BQ-adducted DNAas asubstrate (Figure 3).
Using a pRYG plasmid with a 54 bp RY
repeat, for which topo II has a very high
affinity, it was determined that BQ, at a
concentration 50-fold higher than the con-
centration that inhibits the decatenating
activity of topo II, did not stimulate the
formation oflinear pRYG DNA (Figure 5)
indicative ofan inhibition ofa topo II reli-
gation ofdouble-strand breaks by stabiliza-
tion ofthe covalent topo II-DNA cleavage
complex. Rather, BQ appears to interact
directly with the SH-dependent topo II
presumably at an essential SH group at the
active site of the enzyme. Although these
experiments were carried out in vitro, it is
likely that topo II is accessable to HQ and
BQ in vivo because topo II is present in
high concentration in chromatin as a pro-
tein scaffold (28-30) and because both
HQ and BQ form adducts with nuclear
DNA in myeloid cells (31,32). The inhibi-
tion oftopo II activity by these bioreactive
metabolites of BZ may have implications
for the formation ofdeleterious transloca-
tions that may be involved in the initiation
ofBZ-induced leukemia.
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